Raptiva (efalizumab) is a recombinant humanized monoclonal antibody that binds to human CD11a, the alpha-subunit of Leukocyte Function Antigen-1 (LFA-1) and inhibits the LFA-1/ICAM-1 interaction. Raptiva is an FDA-approved medication for treatment of mild-to-moderate psoriasis.
Psoriasis is a persistent, long-lasting chronic skin disease affecting 2-3 percent of the world's population or more than 125 million individuals. For some, it is just a nuisance. For others, it is disabling.
BioTrends published the second wave of LaunchTrends®: Stelara, highlighting dermatology market trends at three months post launch. The report is based on 76 survey responses and 20 qualitative phone interviews with U.S. dermatologists.
BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the launch of Centocor Ortho-Biotech's Stelara, from product launch through the first six months of availability. Each wave of the report provides quantitative information from 75 unique Dermatologists and qualitative information from a subset of 20.
The 57-year-old lawyer in New York had handily completed the New York Times' Saturday crossword puzzle - the hardest of the week - for years. But one Saturday morning, suddenly he couldn't retrieve the words to fill in the squares.
Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), has announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market.
CytoDyn, Inc. has sent the FDA what the Company believes is a complete response to the agency's preliminary comments on Cytolin, a monoclonal antibody designed to restore immune function in those afflicted with HIV/AIDS.
The U.S. Food and Drug Administration has issued a public health advisory concerning three confirmed, and one possible report of progressive multifocal leukoencephalopathy (PML), a rare brain infection, in patients using the psoriasis drug Raptiva (efalizumab).
The U.S. Food and Drug Administration today announced labeling changes, including a Boxed Warning, to highlight the risks of life-threatening infections, including progressive multifocal leukoencephalopathy (PML), with the use of Raptiva (efalizumab). The labeling changes are based on the FDA's post-market surveillance.
A meta-analysis of four randomized Phase III placebo-controlled trials confirms that the injectable drug Efalizumab, a humanized therapeutic antibody designed to selectively and reversibly block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis, had an acceptable safety and efficacy profile in the treatment of psoriasis in heavy patients, researchers at Mount Sinai School of Medicine announced today.
NICE has today issued guidance for the use of the targeted biological therapies, Enbrel (etanercept) and Raptiva (efalizumab), to treat adult patients with severe plaque psoriasis.
Genentech and XOMA have announced preliminary 30-month (120 weeks) results from an open-label study evaluating the safety and efficacy of long-term continuous treatment with RAPTIVA® (efalizumab) in adults with moderate-to-severe chronic plaque psoriasis.
The U.S. Food and Drug Administration has approved the biologic drug etanercept (brand name Enbrel) to treat chronic, moderate to severe plaque psoriasis in adults.
Genentech, Inc. and XOMA Ltd. today announced preliminary results of a randomized, placebo-controlled Phase II study with RAPTIVA™ (efalizumab) in 107 patients with psoriatic arthritis. The study did not reach statistical significance at 12 weeks (84 days) for the primary endpoint, ACR 20 response. An ACR 20 response indicates at least a 20 percent improvement in an individual's signs and symptoms of arthritis.